Skip to content

ARCH THERAPEUTICS, INC.: 10-Q filed 2015-08-07

What ARCH THERAPEUTICS, INC. reported in its quarterly report filed 2015-08-07 (fiscal Q3 2015): 25 published measures, 74 facts as tagged in accession 0001144204-15-047254.

This filing

Form
10-Q (quarterly report)
Filed
2015-08-07
Fiscal period
fiscal Q3 2015
Accession
0001144204-15-047254 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ARCH THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2015-06-303,317,855USD
At 2014-09-30876,990USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2015-06-309,383,266USD
At 2014-09-307,769,433USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2015-06-30-6,065,411USD
At 2014-09-30-6,892,443USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2015-06-303,273,764USD
At 2014-09-30833,520USD
At 2014-06-301,802,524USD
At 2013-09-30557,319USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2015-04-01 to 2015-06-30-1,395,245USD91
2014-10-01 to 2015-06-30-1,850,066USD273
2014-04-01 to 2014-06-30410,759USD91
2013-10-01 to 2014-06-30-8,777,837USD273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2015-04-01 to 2015-06-300USD91
2014-10-01 to 2015-06-300USD273
2014-04-01 to 2014-06-300USD91
2013-10-01 to 2014-06-300USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2015-06-30-14,624,760USD
At 2014-09-30-12,774,694USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2015-04-01 to 2015-06-3076,804,674shares91
2014-10-01 to 2015-06-3075,396,047shares273
2014-04-01 to 2014-06-3071,949,564shares91
2013-10-01 to 2014-06-3065,933,378shares273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2015-04-01 to 2015-06-3076,804,674shares91
2014-10-01 to 2015-06-3075,396,047shares273
2014-04-01 to 2014-06-3072,084,748shares91
2013-10-01 to 2014-06-3065,933,378shares273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2015-04-01 to 2015-06-30-0.02USD/shares91
2014-10-01 to 2015-06-30-0.02USD/shares273
2014-04-01 to 2014-06-300.01USD/shares91
2013-10-01 to 2014-06-30-0.13USD/shares273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2015-04-01 to 2015-06-30-0.02USD/shares91
2014-10-01 to 2015-06-30-0.02USD/shares273
2014-04-01 to 2014-06-300.01USD/shares91
2013-10-01 to 2014-06-30-0.13USD/shares273

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2014-10-01 to 2015-06-30859,627USD273
2013-10-01 to 2014-06-30748,600USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2015-04-01 to 2015-06-30-1,338,229USD91
2014-10-01 to 2015-06-30-3,863,991USD273
2014-04-01 to 2014-06-30-1,146,296USD91
2013-10-01 to 2014-06-30-3,222,544USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2015-06-303,317,855USD
At 2014-09-30876,990USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2015-04-01 to 2015-06-30134,326USD91
2014-10-01 to 2015-06-30212,647USD273
2014-04-01 to 2014-06-3027,763USD91
2013-10-01 to 2014-06-3083,293USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2015-06-301,891,889USD
At 2014-09-302,723,667USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2015-06-30499,682USD
At 2014-09-30175,832USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2015-04-01 to 2015-06-301,338,229USD91
2014-10-01 to 2015-06-303,863,991USD273
2014-04-01 to 2014-06-301,146,296USD91
2013-10-01 to 2014-06-303,222,544USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2015-04-01 to 2015-06-30525,107USD91
2014-10-01 to 2015-06-301,327,337USD273
2014-04-01 to 2014-06-30320,345USD91
2013-10-01 to 2014-06-30951,101USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2015-06-3092,702,854shares
At 2014-09-3072,076,487shares

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2015-06-3044,091USD
At 2014-09-3043,470USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2015-04-01 to 2015-06-30813,122USD91
2014-10-01 to 2015-06-302,536,654USD273
2014-04-01 to 2014-06-30825,951USD91
2013-10-01 to 2014-06-302,271,443USD273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2014-10-01 to 2015-06-300USD273
2013-10-01 to 2014-06-30322USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2015-06-21 to 2015-07-02100,000USD12
2014-10-01 to 2015-06-30100,000USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2014-10-01 to 2015-06-30323,850USD273
2013-10-01 to 2014-06-30-148,758USD273

Inspect the source

Entity
ARCH THERAPEUTICS, INC. / CIK 0001537561
Captured
SEC response SHA-256
63d0e84748ee59ab7c6817be68d0a32b23d83273213bc50081bb86253a1d4cc2

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001537561.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))